Gadeta
Utrecht
About Gadeta
Gadeta is a research and development company that develops immunotherapies for cancer. It has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (╬│╬┤) T-cell receptors (TCRs) with enhanced anti-cancer reactivity. Gadeta’s new cell-based anti-cancer product called T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs) has strong therapeutic potential for combating and eradicating both hematological and solid tumors. This approach utilizes high-affinity ╬│╬┤ TCRs expressed on ╬▒╬▓ T cells with superior proliferation capacity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.9M
- Funding stage: M&A
- Last round: Corporate Round (Jul 2018)
- Website: gadeta.nl
- Phone: +31 (0) 85 016 44 66
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/gadeta-59676 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.